Juvenescence

Juvenescence Ltd is a biotech company that develops therapies and products to modify aging .In July 2023, AgeX Therapeutics Inc issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness.In July 2021, AgeX Therapeutics Inc had received $1.0 million of cash through a loan from Juvenescence.In February 2021, Juvenescence Limited had entered into Loan Facility Agreement with AgeX Therapeutics Inc. In February 2022, AgeX and Juvenescence entered into a secured convertible promissory note pursuant to which Juvenescence agreed to provide to AgeX a $13.16 million line of credit for a period of 12 months.In December 2020, LyGenesis just had completed over $11 million in private financing of convertible notes led by Juvenescence Ltd